ES2162025T3 - Procedimientos para la determinacion del potencial de trombina endogena (etp) y sustratos de la trombina para su uso en esos procedimientos. - Google Patents

Procedimientos para la determinacion del potencial de trombina endogena (etp) y sustratos de la trombina para su uso en esos procedimientos.

Info

Publication number
ES2162025T3
ES2162025T3 ES96902007T ES96902007T ES2162025T3 ES 2162025 T3 ES2162025 T3 ES 2162025T3 ES 96902007 T ES96902007 T ES 96902007T ES 96902007 T ES96902007 T ES 96902007T ES 2162025 T3 ES2162025 T3 ES 2162025T3
Authority
ES
Spain
Prior art keywords
sample
etp
substrates
group
procedures
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96902007T
Other languages
English (en)
Inventor
Hendrik Coenraad Hemker
Dirk Thomas Sigurd Rijkers
Godefriedus Ignatius Tesser
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of ES2162025T3 publication Critical patent/ES2162025T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0819—Tripeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/974—Thrombin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

UN PROCEDIMIENTO PARA DETERMINAR EL ETP (POTENCIAL DE TROMBINA ENDOGENO) DE UNA MUESTRA, PREFERIBLEMENTE EN UN ENSAYO CONTINUO, INCLUYENDO DICHA MUESTRA UNA ACTIVIDAD ANTICOAGULANTE TOTAL IGUAL O EQUIVALENTE A AL MENOS 0,07 U ISH/ML, EN EL CUAL UN SUSTRATO DE TROMBINA, O UNA SAL DEL MISMO, QUE ES SOLUBLE EN LA MUESTRA, SE APLICA EN UNA MANERA CONOCIDA POR SI MISMA, PARA DETERMINAR EL ETP DE UNA MUESTRA, ESTANDO SELECCIONADO DICHO SUSTRATO DE TROMBINA ENTRE EL GRUPO FORMADO POR SUSTRATOS DE FORMULA P INO, SIENDO DICHO GRUPO NO AROMATICO Y POLAR, VAL ES UN RADICAL VALINA UNIDO MEDIANTE UN ENLACE PEPTIDICO A XAA, XAA ES UN RADICAL AMINOACIDO QUE INCLUYE UN GRUPO GUANIDINO O UN GRUPO UREIDO TERMINAL, SEPARADO POR AL MENOS 2 ATOMOS DE CARBONO DEL ESQUELETO PEPTIDICO, ESTANDO DICHO RADICAL AMINOACIDO UNIDO A S, S ES UN GRUPO SEÑAL TAL COMO UN CROMOFORO, QUE PUEDE SER ENZIMATICAMENTE HIDROLIZADO. TAMBIEN PUEDEN UTILIZARSE OTROS SUSTRATOS, TALES COMO LOS SUSTRATOS QUE INCLUYEN LA ESTRUCTURA ZAA PIPECOLIL YAA RESENTA {SUB,D} TIROSINA, PRO REPRESENTA PROLINA, YAA ES UN RADICAL DE AMINOACIDO DISTINTO DE ARGININA, Y S ES UN MARCADOR SEÑAL. TAMBIEN SON APLICABLES LOS SUSTRATOS BOC TERMINACION DE ETP COMO TALES PUEDEN MEJORARSE MEDIANTE LA ADICION DE HIDROXILAMINA A LA MUESTRA, PARA EVITAR LA DESFIBRINACION DE LA MUESTRA.
ES96902007T 1995-01-10 1996-01-10 Procedimientos para la determinacion del potencial de trombina endogena (etp) y sustratos de la trombina para su uso en esos procedimientos. Expired - Lifetime ES2162025T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP95200043 1995-01-10

Publications (1)

Publication Number Publication Date
ES2162025T3 true ES2162025T3 (es) 2001-12-16

Family

ID=8219949

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96902007T Expired - Lifetime ES2162025T3 (es) 1995-01-10 1996-01-10 Procedimientos para la determinacion del potencial de trombina endogena (etp) y sustratos de la trombina para su uso en esos procedimientos.

Country Status (6)

Country Link
US (1) US6207399B1 (es)
EP (1) EP0802986B1 (es)
AU (1) AU4634896A (es)
DE (1) DE69615339T2 (es)
ES (1) ES2162025T3 (es)
WO (1) WO1996021740A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5708591A (en) * 1995-02-14 1998-01-13 Akzo Nobel N.V. Method and apparatus for predicting the presence of congenital and acquired imbalances and therapeutic conditions
US6321164B1 (en) 1995-06-07 2001-11-20 Akzo Nobel N.V. Method and apparatus for predicting the presence of an abnormal level of one or more proteins in the clotting cascade
US6429017B1 (en) 1999-02-04 2002-08-06 Biomerieux Method for predicting the presence of haemostatic dysfunction in a patient sample
US6898532B1 (en) 1995-06-07 2005-05-24 Biomerieux, Inc. Method and apparatus for predicting the presence of haemostatic dysfunction in a patient sample
US6502040B2 (en) 1997-12-31 2002-12-31 Biomerieux, Inc. Method for presenting thrombosis and hemostasis assay data
AU774889B2 (en) 1999-02-04 2004-07-08 Biomerieux, Inc. A method and apparatus for predicting the presence of haemostatic dysfunction in a patient sample
PT1159448E (pt) * 1999-03-04 2004-08-31 Synapse Bv Determinacao de formas biologicamente activas de enzimas proteoliticas
US6740496B1 (en) 1999-03-04 2004-05-25 Synapse B.V. Determination of biologically active forms of proteolytic enzymes
US7179612B2 (en) 2000-06-09 2007-02-20 Biomerieux, Inc. Method for detecting a lipoprotein-acute phase protein complex and predicting an increased risk of system failure or mortality
EP1367135A1 (en) * 2002-05-29 2003-12-03 Pentapharm AG Improved method for the assessment of thrombin formation in blood or plasma
DE10360628A1 (de) * 2003-12-19 2005-07-21 Dade Behring Marburg Gmbh Kontrollplasma für Thrombinaktivitätstests
DE102004059055A1 (de) 2004-12-07 2006-06-08 Dade Behring Marburg Gmbh Verfahren zur automatischen Bestimmung des endogenen Thrombinpotenzials
DE102005003145B4 (de) * 2005-01-21 2006-10-19 Dade Behring Marburg Gmbh Stablies, chromogenes Flüssigreagenz und dessen Verwendung in gerinnungsdiagnostischen Tests
DE102005008066A1 (de) 2005-02-22 2006-08-24 Haemosys Gmbh Verfahren zur Bestimmung der Gesamtgerinnungsaktivität einer Blut- oder Plasmaprobe
CA2626669A1 (en) * 2005-10-13 2007-04-19 Activesite Pharmaceuticals Methods for indentification of inhibitors of enzyme activity
EP2818871A1 (en) * 2013-06-28 2014-12-31 Roche Diagniostics GmbH Means and methods for universal calibration of anti-Factor Xa tests
WO2018234308A1 (en) 2017-06-20 2018-12-27 INSERM (Institut National de la Santé et de la Recherche Médicale) METHODS FOR IDENTIFYING IF PATIENTS WITH ACUTE CARDIAC DISEASE FAILURE (ICAD) HAVE A HYPERCOAGULABLE CONDITION
EP4239338A1 (de) 2022-03-03 2023-09-06 Siemens Healthcare Diagnostics Products GmbH Globaltest zur feststellung des status des blutgerinnungssystems

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE407571B (sv) 1975-07-11 1979-04-02 Kabi Ab Nya kromogena enzymsubstrat for serinproteaser
US4247454A (en) 1975-07-11 1981-01-27 Ab Kabi Novel chromogenic thrombin substrates
DE3428543A1 (de) 1984-08-02 1986-02-13 Boehringer Mannheim Gmbh, 6800 Mannheim Neue p-phenylendiamin-peptide und diese enthaltende reagenzien zur bestimmung von proteasen des blutgerinnungssystems
FR2611205B1 (fr) * 1987-02-20 1990-03-02 Serbio Dipeptides, procede de preparation et utilisation dans le dosage de proteases
NL8902406A (nl) * 1989-09-27 1991-04-16 Hendrik Coenraad Hemker Prof D Werkwijze voor het bepalen van de endogene trombinepotentiaal van plasma, en bloed alsmede een bij deze werkwijze te gebruiken kit.

Also Published As

Publication number Publication date
US6207399B1 (en) 2001-03-27
EP0802986B1 (en) 2001-09-19
EP0802986A1 (en) 1997-10-29
WO1996021740A1 (en) 1996-07-18
DE69615339T2 (de) 2002-07-04
AU4634896A (en) 1996-07-31
DE69615339D1 (de) 2001-10-25

Similar Documents

Publication Publication Date Title
ES2162025T3 (es) Procedimientos para la determinacion del potencial de trombina endogena (etp) y sustratos de la trombina para su uso en esos procedimientos.
Dartt et al. Vasoactive intestinal polypeptide stimulation of protein secretion from rat lacrimal gland acini
Boué et al. Human sperm-zona pellucida interaction is inhibited by an antiserum against a hamster sperm protein
Konzett et al. Biological activity of synthetic polypeptides with bradykinin‐like properties
Harada et al. Syntheses of amino acids from aliphatic carboxylic acid by glow discharge electrolysis
EP1157029B1 (de) Oligopeptidderivate zur elektrochemischen messung der aktivität von proteasen
Ramarao et al. Receptor-mediated regulation of guanylate cyclase activity in spermatozoa.
ATE44533T1 (de) Hemmen von enzymen.
ATE63748T1 (de) Enzymwiderstandsfaehige immunomodulatorische peptide.
DE69333747D1 (de) Rekombinante zelle, dna-konstruktionen, vektoren und methoden zur expression von phytatabbauenden enzymen in gewünschten verhältnissen
Fundin et al. Different distributions of the sensory and autonomic innervation among the microvasculature of the rat mystacial pad
NO920125D0 (no) Fremgangsmaate for aa bestemme den funksjonelle aktivitetentil fri protein s eller protein c i en plasma-proeve
WO1996021740B1 (en) Methods of determining endogenous thrombin potential (etp) and thrombin substrates for use in said methods
Erdös et al. Renal metabolism of angiotensin I and II.
NOMURA et al. On the “water response” of frog's tongue
Tesfamariam et al. Involvement of the" tethered ligand" receptor in thrombin-induced endothelium-mediated relaxations
KosOWER et al. Membrane-mobility agent-promoted fusion of erythrocytes: fusibility is correlated with attack by calcium-activated cytoplasmic proteases on membrane proteins.
Ecobichon et al. Some properties of the soluble esterases of human liver
USRE35886E (en) Phosphonic acid derivatives and use thereof
Sterchi et al. Peptide hydrolases of the human small intestinal mucosa: identification of six distinct enzymes in the brush border membrane
Goldman et al. Permeation and stereospecificity of hydrolysis of peptide esters within intact lysosomes in vitro
Yamaguchi et al. Modulation of pulmonary artery contraction by endothelium-derived relaxing factor
Cai et al. Localization of neuropeptide Y and atrial natriuretic peptide in the endothelial cells of human umibilical blood vessels
Eakin et al. Parietal eye nerve in the fence lizard
Rhoads et al. Proline transport by synaptosomal membrane vesicles isolated from rat brain: energetics and inhibition by free fatty acids

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 802986

Country of ref document: ES